Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Hematology/Oncology Fellowship, Medicine, Duke University School of Medicine 2013 - 2016
  • Internal Medicine Residency, Medicine, Duke University School of Medicine 2010 - 2013
  • M.D., University of North Carolina at Chapel Hill School of Medicine 2010
• 

  Duke Appointment History

  • Medical Instructor in the Department of Medicine, Medicine, Medical Oncology, Medicine 2016 - 2018
• Recognition
• 

  In the News

  • FEB 12, 2019

    Duke Health News

    Study: Black Men With Prostate Cancer Show Better Survival Rates With New Drugs
• Research
• 

  Selected Grants

  • A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint i awarded by Seattle Genetics, Inc 2018 - 2023
  • PCRP Clinical Consortium: Duke University Clinical Research Site awarded by Department of Defense 2007 - 2021
  • PCF Young Investigator Award awarded by Prostate Cancer Foundation 2018 - 2021
  • A Phase 1b/2 Study of Enzalutamide Plus CC-115 in Men with Castration-Resistant Prostate Cancer (CRPC); Sponsor ¿ Memorial Sloan Kettering Cancer Center awarded by The Prostate Cancer Clinical Trials Consortium 2018 - 2020
  • CTC-Immune Checkpoints awarded by Janssen Research & Development, LLC 2016 - 2020
  • An IND-enabling Trial to Determine the Number and Volume of Injections Necessary for Adequate Distribution Throughout Cancer Metastases and to Validate Poliovirus Receptor (CD155) Expression in PC awarded by V Foundation for Cancer Research 2016 - 2019
  • Bayer-Exini Radium-223 Retrospective Study awarded by Bayer Healthcare Pharmaceuticals Inc 2016 - 2019
• Publications & Artistic Works
• 

  Selected Publications

  • Academic Articles

    • McNamara, M, Sweeney, C, Antonarakis, ES, and Armstrong, AJ. "The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation." Prostate Cancer and Prostatic Diseases 21, no. 3 (September 2018): 306-318. (Review)  Full Text

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.